Skip to content
✕

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Consumer Health
Janssen
MedTech
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
France
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

More HIV News

Innovation
March 29, 2022
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
Innovation
March 24, 2022
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Innovation
February 01, 2022
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
Innovation
December 01, 2021
This Ring May Just Help Protect Women Against HIV
Our Company
December 01, 2021
World AIDS Day 2021: How Far We’ve Come, and Yet to Go
Innovation
November 30, 2021
How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
Our Company
August 31, 2021
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Innovation
July 26, 2021
The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
Innovation
July 22, 2021
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Personal Stories
July 19, 2021
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
Our Company
July 15, 2021
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
Innovation
June 01, 2021
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
Our Company
March 06, 2021
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
Innovation
January 21, 2021
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Innovation
December 21, 2020
Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Innovation
October 16, 2020
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
Innovation
March 20, 2020
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
Innovation
March 11, 2020
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
Our Company
October 04, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Innovation
September 04, 2019
Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
Innovation
July 23, 2019
Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen
We’re Committed to Helping Lead the Fight Against HIV/AIDS
Read about the many ways Johnson & Johnson is working to #makeHIVhistory.
Learn more
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue